open access

Vol 19, No 2 (2016)
Original articles
Published online: 2016-07-29
Submitted: 2016-05-27
Accepted: 2016-06-29
Get Citation

99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors

Mate Trogrlic, Stanko Tezak
DOI: 10.5603/NMR.2016.0016
·
Pubmed: 27479884
·
Nucl. Med. Rev 2016;19(2):74-80.

open access

Vol 19, No 2 (2016)
Original articles
Published online: 2016-07-29
Submitted: 2016-05-27
Accepted: 2016-06-29

Abstract

BACKGROUND: Aim of this study was to determine the value of technetium-99m-hydrazinonicotinyl-Tyr3-octreotide (99mTc-ED­DA/HYNIC-TOC) in patients with somatostatin receptor (SSR) positive tumors of head and neck region.

MATERIAL AND METHODS: A total number of 16 patients were enrolled in this study. Planar whole body (WB) and single photon emission computed tomography (SPECT) images were acquired at 2 and 4 hours after the injection of approximately 670 MBq of 99mTc-EDDA/HYNIC-TOC. Additional single photon emission computed tomography/computed tomography (SPECT/CT) images of the head and neck region were acquired at 4h post tracer injection. Clinical and imaging follow up were taken as the reference standard.

RESULTS: There were 10 female and 6 male patients of age 57.7 ± 12.9 years (58.5; 32–78) years. 99mTc-EDDA/HYNIC-TOC somatostatin receptor scintigraphy (SRS) was TP in 13 patients, TN in two and FP in one. Follow up period for SRS was 31.1 ± 19.4 (29; 2–63) months. 99mTc-EDDA/HYNIC-TOC scintigraphy provided additional information in 50% of patients, with impact on patient management in the same percentage of patients. Distant metastases were found in nine out of 16 patients (56%). 99mTc-EDDA/HYNIC-TOC SRS had sensitivity of 100% (75.3–100%), specificity of 66.7% (9.4–99.2%), accuracy of 93.7%, positive predictive value of 92.9% (66.1–99.8%), and negative predictive value of 100% (15.8–100%).

CONCLUSION: Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC is very useful imaging method in the evalu­ation of patients with SSR positive tumors of head and neck region.

Abstract

BACKGROUND: Aim of this study was to determine the value of technetium-99m-hydrazinonicotinyl-Tyr3-octreotide (99mTc-ED­DA/HYNIC-TOC) in patients with somatostatin receptor (SSR) positive tumors of head and neck region.

MATERIAL AND METHODS: A total number of 16 patients were enrolled in this study. Planar whole body (WB) and single photon emission computed tomography (SPECT) images were acquired at 2 and 4 hours after the injection of approximately 670 MBq of 99mTc-EDDA/HYNIC-TOC. Additional single photon emission computed tomography/computed tomography (SPECT/CT) images of the head and neck region were acquired at 4h post tracer injection. Clinical and imaging follow up were taken as the reference standard.

RESULTS: There were 10 female and 6 male patients of age 57.7 ± 12.9 years (58.5; 32–78) years. 99mTc-EDDA/HYNIC-TOC somatostatin receptor scintigraphy (SRS) was TP in 13 patients, TN in two and FP in one. Follow up period for SRS was 31.1 ± 19.4 (29; 2–63) months. 99mTc-EDDA/HYNIC-TOC scintigraphy provided additional information in 50% of patients, with impact on patient management in the same percentage of patients. Distant metastases were found in nine out of 16 patients (56%). 99mTc-EDDA/HYNIC-TOC SRS had sensitivity of 100% (75.3–100%), specificity of 66.7% (9.4–99.2%), accuracy of 93.7%, positive predictive value of 92.9% (66.1–99.8%), and negative predictive value of 100% (15.8–100%).

CONCLUSION: Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC is very useful imaging method in the evalu­ation of patients with SSR positive tumors of head and neck region.

Get Citation

Keywords

neuroendocrine tumors, receptors, somatostatin, tomography, emission-computed, single-photon, technetium 99m EDDA-HYNIC-Tyr (3)-octreotide

About this article
Title

99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors

Journal

Nuclear Medicine Review

Issue

Vol 19, No 2 (2016)

Pages

74-80

Published online

2016-07-29

DOI

10.5603/NMR.2016.0016

Pubmed

27479884

Bibliographic record

Nucl. Med. Rev 2016;19(2):74-80.

Keywords

neuroendocrine tumors
receptors
somatostatin
tomography
emission-computed
single-photon
technetium 99m EDDA-HYNIC-Tyr (3)-octreotide

Authors

Mate Trogrlic
Stanko Tezak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl